BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26474013)

  • 1. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.
    Seto WK; Tanaka Y; Wong DK; Shinkai N; Cheung KS; Liu KS; Fung J; Lai CL; Yuen MF
    Liver Int; 2016 May; 36(5):642-50. PubMed ID: 26474013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK; Wong DK; Fung J; Huang FY; Lai CL; Yuen MF
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
    Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
    Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.
    Seto WK; Wong DK; Kopaniszen M; Proitsi P; Sham PC; Hung IF; Fung J; Lai CL; Yuen MF
    Clin Infect Dis; 2013 Jun; 56(12):1695-703. PubMed ID: 23449268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients.
    Hu HH; Liu J; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; Quan Y; Xia NS; Chen CJ; Chen PJ; Yang HI
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):172-181.e1. PubMed ID: 29753083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.
    Seto WK; Cheung KS; Wong DK; Huang FY; Fung J; Liu KS; Lai CL; Yuen MF
    J Gastroenterol; 2016 May; 51(5):487-95. PubMed ID: 26446756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.
    Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Wang LY; You SL; Iloeje UH; Chen CJ;
    Gastroenterology; 2010 Aug; 139(2):474-82. PubMed ID: 20434450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection.
    Liu J; Lee MH; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; Wang LY; You SL; Hsiao CK; Yang HI; Chen CJ
    J Hepatol; 2013 May; 58(5):853-60. PubMed ID: 23246508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.
    Oliveri F; Surace L; Cavallone D; Colombatto P; Ricco G; Salvati N; Coco B; Romagnoli V; Gattai R; Salvati A; Moriconi F; Yuan Q; Bonino F; Brunetto MR
    Liver Int; 2017 Nov; 37(11):1622-1631. PubMed ID: 28296013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
    Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.
    Boyd A; Canini L; Gozlan J; Lascoux-Combe C; Miailhes P; Fonquernie L; Girard PM; Lacombe K
    J Clin Virol; 2017 Oct; 95():55-60. PubMed ID: 28869890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort.
    Zhu L; Zhai X; Wang Q; Jiang J; Peng H; Song C; Ge Z; Qian J; Zhou M; Zhou Y; Xu J; Liu H; Hang D; Hu Z; Shen H; Zhu F
    J Viral Hepat; 2018 Dec; 25(12):1588-1598. PubMed ID: 30112835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.
    Seto WK; Wong DK; Fung J; Huang FY; Liu KS; Lai CL; Yuen MF
    Clin Microbiol Infect; 2014 Nov; 20(11):1173-80. PubMed ID: 24975365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
    Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
    J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance.
    Arase Y; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Sato J; Kobayashi M; Ikeda K; Kumada H
    Intervirology; 2007; 50(3):161-5. PubMed ID: 17259734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.